# Kao vs Rohto Pharmaceutical

> Unit: JPY millions (ratios in %)
> Periods: Kao = FY ending Dec 2025, consolidated, IFRS / Rohto Pharmaceutical = FY ending Mar 2026, consolidated, J-GAAP
> Retrieved: 2026-09-30T19:07:57.678Z

| Metric | Kao | Rohto Pharmaceutical |
| --- | ---: | ---: |
| Revenue | 1,688,633 | 343,725 |
| Operating income | 164,069 | 41,118 |
| Net income | 120,081 | 34,247 |
| COGS ratio | 60.4% | 43.9% |
| Operating margin | 9.7% | 12.0% |
| Net margin | 7.1% | 10.0% |
| FCF margin | 7.6% | 6.3% |
| Period | FY ending Dec 2025 | FY ending Mar 2026 |
| Source | S100XT6G | S100YE5N |

## Five-axis industry profile

Each axis shows a rank within that company's primary industry, so peer groups may differ. Missing values are labeled unavailable; no combined score is calculated. Industry rank is not an investment recommendation.

| Axis | Kao | Rohto Pharmaceutical |
| --- | ---: | ---: |
| Revenue growth | 55 (10 peers) | 65.9 (22 peers) |
| Profitability | 94.4 (9 peers) | 86.5 (26 peers) |
| Cash conversion | 38.9 (9 peers) | 61.4 (22 peers) |
| Efficiency | 65 (10 peers) | 21.2 (26 peers) |
| Financial strength | — | — |

## Company details

- https://vizora.meequs.com/en/company/kao/md
- https://vizora.meequs.com/en/company/rohto-pharmaceutical/md

## Definitions

- Amounts are in millions of JPY (rounded). The period is stated in each table heading
- Operating margin = operating income ÷ revenue. Net income is attributable to owners of the parent when disclosed
- Free cash flow (FCF) = operating cash flow − capital expenditure
- ¥100 model = breakdown per ¥100 of revenue (rounded so parts sum to 100)
- Segment revenues include inter-segment sales and may not sum to consolidated revenue
- Source IDs are EDINET document IDs (docID). "算出" (derived) means computed from other disclosed values
- All figures are extracted mechanically from filings. AI-written text never generates figures
- Source: company filings submitted to EDINET (Financial Services Agency of Japan). Figures were extracted, edited and processed, and charts and text were created, by Vizora — not by the FSA (used under the Public Data License v1.0).